Moleculin Biotech, Inc. (NASDAQ:MBRX) Stock Short Interest Rises 61.5%

Moleculin Biotech, Inc. (NASDAQ:MBRX) saw a significant increase in short interest in September. As of September 15th, there was short interest totaling 287,608 shares, an increase of 61.5% from the August 31st total of 178,126 shares. Approximately 1.8% of the company’s stock are sold short. Based on an average trading volume of 652,899 shares, the short-interest ratio is currently 0.4 days.

Wall Street Analysts Forecast Growth

MBRX has been the topic of several recent research reports. HC Wainwright dropped their price target on shares of Moleculin Biotech to $3.00 and set a “buy” rating on the stock in a research report on Friday, August 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Finally, Wall Street Zen raised Moleculin Biotech from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Moleculin Biotech presently has an average rating of “Hold” and an average price target of $3.00.

Moleculin Biotech Stock Performance

Shares of Moleculin Biotech stock traded down $0.02 during mid-day trading on Wednesday, hitting $0.51. 667,570 shares of the stock were exchanged, compared to its average volume of 653,760. Moleculin Biotech has a 12 month low of $0.16 and a 12 month high of $15.75. The company has a 50-day simple moving average of $0.78 and a 200 day simple moving average of $1.87. The company has a market capitalization of $9.84 million, a P/E ratio of -0.07 and a beta of 1.92.

Moleculin Biotech (NASDAQ:MBRX) last released its earnings results on Thursday, August 13th. The company reported ($1.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.55) by $0.15. Analysts predict that Moleculin Biotech will post -2.37 EPS for the current year.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for cancers that are difficult to treat or have limited therapeutic options. The company’s research programs target cancer-cell survival mechanisms, drug resistance and tumor metabolism.

Moleculin’s lead product candidate is annamycin, a liposomal formulation of doxorubicin designed to retain anticancer activity while reducing the risk of cardiotoxicity associated with some conventional anthracyclines.